LY2605541 (LY) exhibits a Flatter Glucodynamic profile than insulin Glargine (GL) at steady state in subjects with Type 1 Diabetes (T1D)

Aim: The aim of this open-label, randomized Phase2 crossover substudy was to investigate the glucodynamic profile of LY, a novel basal insulin analog with prolonged duration of action, compared to GL. Methods: 23 T1D patients underwent 24h Biostator-controlled euglycemic clamps after 8-wks treatment with GL or LY. Clinically titrated basal insulin doses (LY: 16 – 64U, GL: 19 – 60U) were administered the morning of the clamp. Locally weighted scatterplot smoothing (LOESS) function was applied to individual glucose infusion rate (GIR)-versus-time profiles in each treatment group and/or period. Mean LOESS fits of d…